Milrinone

Milrinone

The molecular structure of Milrinone.

Milrinone is a phosphodiesterase 3 inhibitor used primarily in the treatment of heart failure. On January 8, 2018, the United States Food and Drug Administration (FDA) designated Milrinone as an orphan drug for the treatment of right heart failure (RHF) in patients with left ventricular assist devices (LVADs). This designation highlights the drug's importance in treating a condition affecting a relatively small patient population, underscoring the commitment to advancing care for individuals with severe cardiac conditions. The Baker Heart and Diabetes Institute, known for its research and development in heart and diabetes care, manufactures and distributes Milrinone.

Pharmacology

Milrinone works by inhibiting phosphodiesterase 3 (PDE3), which increases cyclic adenosine monophosphate (cAMP) in heart muscle cells. This action leads to improved myocardial contractility and vasodilation, thereby enhancing cardiac output and reducing the symptoms of heart failure.

Milrinone

Therapeutic Uses

While Milrinone is used for the management of acute decompensated heart failure, its role in supporting patients with LVADs, particularly those with right heart failure, is of significant interest. The orphan drug designation by the FDA for this specific use recognizes the critical need for effective therapies in this high-risk patient group.

Administration

Milrinone can be administered intravenously for acute heart failure management, offering rapid onset of action. Its use in LVAD patients requires careful monitoring by healthcare professionals to optimize dosages and manage potential side effects effectively.

Side Effects

Common side effects associated with Milrinone include:

• Arrhythmias
• Hypotension
• Headaches
• Nausea

Development and Distribution

The Baker Heart and Diabetes Institute, with its focus on cardiovascular diseases and diabetes, oversees the development and distribution of Milrinone. The institute's involvement ensures that the drug is produced according to high-quality standards and is readily available to those in need.

See Also

• Phosphodiesterase inhibitor
• Heart failure
• Left ventricular assist device (LVAD)
• Orphan drug

External Links

• FDA - U.S. Food and Drug Administration
• Baker Heart and Diabetes Institute

Milrinone Resources
Latest articles Most recent articles Ongoing trials	Wikipedia

Resources

Frequently asked questions

‎